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Background: Sickle cell anaemia (SCA) is a major cause of morbidity and 
mortality in Africa where there is no readily available effective treatment. 
This study was designed to determine the haematological values that can be 
used in monitoring the status and management of SCA patients. 
Method: A prospective study of 200 patients (81.3%) in steady state, 46 
patients (18.7%) during vaso-occlusive crisis (VOC) and 84 control subjects 
seen between August 2001 and July 2002 in 3 centers in Benin City, Nigeria 
had their blood samples analyzed within two hours of collection. Automated 
Coulter Counter was used to determine the complete blood counts while the 
foetal haemoglobin (HbF) was estimated by the modified Betke method and 
haemoglobin A2 by HbS-free microcolumn chromatography. 
Results: The mean cell volume (MCV), mean cell haemoglobin (MCH) and 
mean cell haemoglobin concentration (MCHC) in steady state were 79.38fl ± 
22.41, 28.31pg ± 3.58 and 32.56g/dl ± 2.27 while in VOC they were 85.50fl 
± 8.14, 28.79pg ± 2.78 and 33.76g/dl±3.44 respectively. The red cell 
distribution width (RDW), haemoglobin A2 and F in steady state were 
23.76% ± 6.49, 4.52% ±1.16 and 2.17% ±1.81 while during VOC they were 
21.62% ±5.11, 3.82%±1.27 and 2.05%±1.19 respectively. The neutrophil 
count (P<0.01), MCV (P<0.01) and MCHC (P<0.05) were significantly 
higher during VOC than steady state while the RDW (P<0.05) and 
haemoglobin A2 were significantly higher in steady state than during VOC.  
Conclusion: Parameters, which are not usually reported in previous studies, 
have been shown in steady state and VOC. 





















Introduction :  La drépanocytose est la cause principale de la morbidité et 
mortalité  en Afrique où il n’ y a aucun traitement efficace facilement 
dispobible. L’objet de cette étude est de déterminer des valuers 
hématologiques qu’on pourrait utiliser dans la surveillance du statut et la 
prise en charge des patients atteints de la drépanocytose. 
Méthode : Une étude potentielle composée de 200 patients soit 81,3% dans  
un état normal,  46 patients  soit 18,7% pendant la crise vasco-occlusive 
(VOC) et 84 sujets contôles vus entre août 2001 et juillet 2002 dans 3 centres 
à la ville de Benin, Nigéria avaient eu leur prise du sang analysé en moins de 
deux heures de la collection  Décompte Coulter automatisé était utilié pour 
déterminer le décompte du sang total tandis que l’hémoglobine foetale (hbF) 
était  évaluée à travers la chromatographie  microcolumn libre – HbS. 
Résultats : Le moyen du volume de la cellule (MVC), d’hémoglobine 
cellulaire moyenne (HCM) et la concentration hèmoglobine cellulaire 
moyenne (CHCM) dans un état stable étaient 79,38fl+- 22,41, 28,31pg +- 
3,58 et 32,56/dl+- 2,27 tandis que dans le VOC ils étaient  85,50fl+- 
8;14,28,79pg +- 33,76g/dl+- 3,44 respectivment. La largeur de la distribution 
du globule rouge (LDGR), hémoglobine A2  et F dans un état stable étaient 
23,76 %+-6.49,4,52%+-1,16 et 2,17%+-1,81 tandis que pendant le VOC
 








 ils étaient  21,62%%+- 5,11, 3,82%+- 1,27 et 2,05%+-1,19 respectivement, 
le décompte neutrophil, (P<0,01), MVC (P<0,01) et CHCM (P<0,05) étaient 
sensiblement très  élevé pendant VOC que était stable tandis que la LDGR 
(P<0,05) et hémoglobine A2   étaient sensiblement plus élevée dans l’état 
stable plus que pendant VOC. 
Conclusion : Des paramètres, qu’on n’avait pas rapporté normalement dans 






Patients with sickle cell disease (SCD) have varying 
amounts of abnormal haemoglobin called the sickle 
cell or “S” haemoglobin in their erythrocytes.1 Sickle 
cell anaemia (SCA) is due to the substitution of 
adenine with thymine in the glutamic DNA codon 
(GAG→GTG), which results in turn, in substitution 
of β6 valine for glutamic acid. 
The disease accounts for over 60% of the world’s 
major haemoglobinopathies with an estimated 2-3 
million Nigerians affected by the “S” gene.2 The 
extent of the problems of SCD in Nigerian cannot 
therefore be overemphasized because of the “S” gene 
said to be between 25-30%.3  The majority of the 
patients born to rural dwellers do not usually survive 
childhood.4 In Nigeria, two out of every one hundred 
have SCA.4 Furthermore, there is no widely 
acceptable and readily available cure for patients with 
SCA at present. Curable methods such as gene 
therapy and bone marrow transplantation, which may 
be associated with several complications, are not 
readily available in developing nations. It is therefore 
imperative on us to be well acquainted with routine 
haematological parameters that may assist in 
managing these patients adequately in developing 
countries. 
Many patients with SCA are in reasonably good 
health most of the time and achieving a steady state 
level of fitness. This state of relative well-being is 
periodically interrupted by crisis of which the vaso-
occlusive crisis (VOC) is the most common and 
hallmark of patients with SCD.5 The importance of 
early recognition and subsequent clinical and 
haematological assessment of the disease are greatly 
facilitated by familiarity with the patient’s steady 
state. A patient with SCA is said to be in steady state 
when there is absence of infection, acute complicating 
factors or acute clinical symptoms or crisis for at least 
three months.6 Crisis refers to episodes of acute illness 
attributable to the sickling phenomenon in which 
there is a sudden deviation for the worse or a sudden 
exacerbation of symptoms and signs of patients with 
SCA who had hitherto been in stable condition.7 The 
occurrence of crisis makes the disease incapacitating 
to the patient and frustrating to parents and 
physicians. 
Many previous studies have lumped the 
haematological variables in steady state and crisis 
together. This study will determine if there is a 
difference in the haematological variables between 
steady state period and VOC. Furthermore, many of 
the established values were determined over a decade 
ago. Various changes in therapeutic, economic, social, 
technological measures have taken place since then. 
This study will therefore determine if these changes 
have affected what we accept as the ‘normal’ values 
in these patients. Less commonly determined 
variables such as erythrocyte indices, red cell 
distribution width, haemoglobin A2 and haemoglobin 




Materials and Method 
 
Patients 
 Two hundred patients with a diagnosis of SCA 
attending the consultant outpatient clinic at the 
University of Benin Teaching Hospital, Central 
Hospital and Sickle Cell Center in Benin City, Nigeria 
between August 2001 and July 2002 in their steady 
state were recruited into the study after obtaining 
informed consent. Forty-six patients in VOC 
presenting to the consultant outpatient and casualty 
departments were also recruited. Their blood samples 
were analyzed within two hours of collection.     
 
Inclusion criteria 
1. Known patients with SCA (HbSS as diagnosed 
by cellulose acetate electrophoresis at pH 8.6) in 
the steady state i.e. established by a steady 
haematocrit and haemoglobin values over a given 
period of 2-3 clinic visits at 4-6 weeks intervals 
and a state of well being without any symptoms 
or signs suggestive of crisis established by a 
careful history and complete physical 
examination.8  
2. Known patients with SCA considered clinically 
to be in VOC by the following criteria: Bone and 
joint pains or multiple sites of pain, requirement 
for analgesics and patients considering the 




1. Any patient with disorders that may affect the 
haematological values such as renal disease. 
2. Pregnancy 
3. Any patient with recent blood transfusion during 
the preceding three months.  
 
Sample collection 
5ml of venous blood was collected by clean 
venepuncture from each patient via the antecubital 
vein using a plastic syringe with minimum stasis, into 
commercially prepared concentrations of sequestrene 
Ethylene Di-amine Tetracetic Acid (EDTA) bottles.
 
Haematological values in sickle cell anaemia in steady state and during vaso-occlusive crisis. Omoti C. E.  64 
Each sample was mixed gently and thoroughly to 
prevent cell lysis and ensure anticoagulation. An 
aliquot was used to determine complete blood counts 
(CBC) within 2 hours of collection while the 
remainder was used to prepare haemolysate for 
haemoglobin A2 and foetal haemoglobin estimation. 
For patients in VOC, samples were collected and 
analyzed within 24 hours of onset of pain. 
 
Methodology 
1. The complete blood counts (CBC) were analyzed 
using the automated COULTERR AC T diffTM 
Analyzer (1997 model). The CBC includes 
haemoglobin, haematocrit, total white blood cell 
count and differential, platelet count, mean cell 
volume, mean cell haemoglobin, mean cell 
haemoglobin concentration and red cell 
distribution width.  
2. Measurement of HbA2 was done by the 
chromatographic-spectrophotometric ion 
exchange-HbS interference free technique using 
the BiosystemR kit with ISO 9001 certificate reg: 
091006696.The procedure recommended by the 
manufacturer was applied. HbA2 percentage was 
calculated using the formula (A415=Absorbance at 
415nm, HbA =Total haemoglobin): O
                                  A415 HbA2
      %HbA = __________________________ x     100             2
                     A415HbA2 + 3 x A 415HbA0                                                                                   
Two hundred and forty-six patients with a diagnosis 
of SCA who met the inclusion criteria were recruited 
comprising of 116 males (47.2%) and 130 females 
(52.8%). Two hundred patients (81.3%) were seen in 
steady state and forty-six patients (18.7%) were seen 
during VOC. The mean age was 23.69 years 
(S.D±10.94) with a range of 5 years to 70 years.  
3. Measurement of HbF was done by the modified 
Betke method  because it is reliable and designed 
for quantitation of small levels of HbF (below 10-
15%). HbF percentage was calculated using the 
formula: 
9
       %HbF   = A413 filtrate   x     100 
  A413 standard   x   20 
Precautions taken to ensure reliable results included: 
1. All samples were subjected to the same analytical 
procedure e.g. haemolysate preparation for the 
estimation of HbA2 and HbF. 
2. It was ensured that Betke’s solution was not 
frothy (indicating contamination by detergent), as 
this will reduce the resistance of haemoglobin F 
alkaline denaturation leading to falsely low result. 
3. Reagents and columns used for HbA2 were 
allowed to warm to room temperature (failure to 
do this will give results up to 25% lower than 
expected). 
4. The sample used for HbA2 was allowed to be 
completely absorbed into the resin. The 
haemolysate will have a glossy appearance on 
complete absorption by the resin. Upon complete 
absorption, but without drying out, the top of the 
resin will have a dull malte-like appearance.  
 
Data analysis 
Data was analyzed by SPSS version 3.0. An initial 
frequency count of all variables was done. The means 
ranges and standard deviations (S.D) of the 
haematological values in the steady state, during VOC 
and in controls were calculated. Values in the steady 
state were compared with values in VOC using the 
student‘t’ test. Values in steady state and VOC were 





The haematological values obtained in steady state 
and VOC is shown in table1. There was a statistically 
significant difference in the neutrophil count 
(P<0.01), mean cell volume (P<0.01), mean cell 
haemoglobin concentration (P<0.05), red cell 
distribution width (P<0.05) and haemoglobin A2 
(P<0.01). The haematological variables in the steady 
state and in control are shown in table 2. The 
haematological values in VOC and in control are 
shown in table 3. There was a statistical difference in 
all the variables tested except the mean cell volume 
and the mean cell haemoglobin concentration.
 
 
Table 1: Haematological values in sickle cell anemia patients in steady state and vaso-occlussive crisis 
 
 
Variable     HbSS (n=200) 
Steady statee 
Mean ± S.D 
HbSS (n=46) 
Vaso-occlusive crisis 
Mean ± S.D   
P 
Haemoglobin (g/dl)      7.54 ± 2.26 7.77±2.25 >0.05      
Haemoglobin (l/l) 0.23 ± 0.06    0.24±0.06 >0.05   
White Blood Cell Count (x 109/l) 12.72± 7.98    13.67±7.57 >0.05   
Neutrophils (x 109/l)     5.2 ± 1.6 6.4 ± 2.0     <0.01 
Lymphocytes (x 109/l) 6.5 ± 1.6 6.3 ± 2.0 >0.05 
Monocytes (x 109/l) 1.0 ± 0.78 1.0 ± 0.04 >0.05 
Platelet count (x 109/l) 342.62±143.03 352.89±144.78 >0.05 
Mean Cell Volume (fl) 79.38±22.41     85.50±8.14     <0.01 
Mean Cell Haemoglobin (pg) 28.31±3.58    28.79±2.78 >0.05   
Mean Cell Haemoglobin                                          
Concentration (g/dl) 
32.56±2.27 33.76±3.44 <0.05 
Red Cell Distribution Width (%) 23.76±6.49 21.62± 5.11    <0.05 
Haemoglobin F (%) 2.17±1.81 2.05 ± 1.19   >0.05   
Haemoglobin A2 (%) 4.52±1.16 3.82 ± 1.27 <0.01 
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Table 2: Haematological values in sickle cell anaemia patients in the steady state and in control 
 
Variable     HbSS (n=200) 
Steady state 
Mean ± S.D 
HbAA (n=84) 
Control 
Mean ± S.D   
P 
Haemoglobin (g/dl)      7.54 ± 2.26 12.93±2.22 <0.01 
Haemoglobin (l/l) 0.23 ± 0.06    0.37±0.06 <0.01 
White Blood Cell Count (x 109/l) 12.72± 7.98    5.71±0.97 <0.01 
Neutrophils (x 109/l)     5.2 ± 1.6 2.3 ± 0.51    <0.01 
Lymphocytes (x 109/l) 6.5 ± 1.6 2.9 ± 0.69 <0.01 
Monocytes (x 109/l) 1.0 ± 0.78 0.4 ± 0.17   <0.01 
Platelet count (x 109/l) 342.62±143.03 304.24±61.47 <0.01 
Mean Cell Volume (fl) 79.38±22.41     8 4.46±5.26    <0.01 
Mean Cell Haemoglobin (pg) 28.31±3.58    30.16±2.99 <0.01 
Mean Cell Haemoglobin                                                 
Concentration (g/dl) 
32.56±2.27 2.62± 1.04 <0.01 
Red Cell Distribution Width (%) 23.76±6.49 2.62 ± 1.04    <0.01 
Haemoglobin F (%) 2.17±1.81 1.28 ± 1.04    <0.01     
Haemoglobin A2 (%) 4.52±1.16 2.13±0.98 <0.01 
 
 
Table 3: Haematological values in sickle cell anaemia patients in vaso-occlusive crisis and in control 
 
 
Variable     HbSS (n=46) 
Vaso-occlusive crisis 
Mean ± S.D   
HbAA (n=84) 
Control 
Mean ± S.D   
P 
Haemoglobin (g/dl)      7.77±2.25 12.93±2.22 <0.01 
Haemoglobin (l/l) 0.24±0.06 0.37±0.06 <0.01 
White Blood Cell Count (x 109/l) 13.67±7.57 5.71±0.97 <0.01 
Neutrophils (x 109/l)     6.4 ± 2.0   2.3 ± 0.51    <0.01 
Lymphocytes (x 109/l) 6.3 ± 2.0 2.9 ± 0.69 <0.01 
Monocytes (x 109/l) 1.0 ± 0.04 0.4 ± 0.17   <0.01 
Platelet count (x 109/l) 352.89±144.78 304.24±61.47  <0.05   
Mean Cell Volume (fl) 85.50±8.14     8 4.46±5.26     >0.05   
Mean Cell Haemoglobin (pg) 28.79±2.78 30.16±2.99 <0.01 
Mean Cell Haemoglobin                                      
Concentration (g/dl) 
33.76±3.44 2.62± 1.04 >0.05 
Red Cell Distribution Width (%) 21.62± 5.11    2.62 ± 1.04    <0.01 
Haemoglobin F (%) 2.05 ± 1.19   1.28 ± 1.04    <0.01     




It is now believed that with purposeful alteration of 
certain red cell parameters, it is possible to improve 
the haematological and biological characteristics of 
SCA patients and consequently improve the clinical 
course of the disease. These parameters include 
increasing intra-corpuscular HbF concentration as 
well as cellular hydration, increasing HbA2, MCV 
below 72fl and MCHC below 32g/dl.10   
The mean age was 23.69 years (S.D±10.94). The 
peak age incidence in this study was in the third 
decade. This is high because the study was carried out 
mainly in adult clinics. Life expectancy of SCA 
patients is said to be short.11,12  The 1989 cooperative 
study of SCD (CSSCD) revealed that approximately 
85% of children and adolescents with SCA and 95% 
with SC survived to 20 years of age in contrast to the 
estimated 14.3 years in 1973.11 There were more 
females 130 (52.8%) than males 116 (47.2%) in this 
study. A review of the age and sex distribution in this 
study showed that only females were seen above the 
age of 50 years. This is in agreement with the findings 
that females may have longer life expectancy, which 
reported 42-53 years for men and 48-58 years for 
women.12          
The mean haemoglobin and Hct values in steady 
state, VOC and controls are in agreement with 
previous studies.13 The SCA patients are continually 
haemolysing their red cells with a short survival rate 
of the erythrocytes between 12-14 days.13 Hence, the 
haemoglobin and Hct values are usually lower than 
normal healthy individuals. This is shown in this 
study where the haemoglobin and Hct values in steady 
state and VOC were significantly less than in control 
(P<0.01). The paradox was found in the results for the 
controls where a mean haemoglobin value of 12.9g/dl 
and Hct value of 0.37l/l were recorded as compared to 
Ezeilo’s report of 15.6g/dl and 0.49l/l.14 This could be 
as a result of the downturn in our economy.  There 
was however no statistically significant difference in 
haemoglobin and Hct values in steady state and VOC. 
This is in agreement with another study carried out in 
Benin City.13    
The mean total white blood cell count (WBCC) 
recorded in this study for steady state, VOC and 
control are of similar values to those reported by other 
authors.9,15 As expected, the total WBCC and 
differential counts in steady state and VOC were 
significantly higher than in controls (P<0.01).This is 
expected because of the basic mechanisms which 
cause an increase concentration of neutrophils in
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venous blood of SCA patients which include 
demargination of intravascular neutrophils, 
accelerated release from the bone marrow and 
reduction in the rate at which neutrophils leave the  
blood.15  
Patients with SCA are known to have significantly 
higher mean total WBCC and differentials than 
people with AA genotype thereby blunting out the 
utility of this measurement in assessment of 
infection.16 Akinola et al17 suggested the generation of 
a covert inflammatory response leading to the release 
of cytokine mediators, one of whose main function is 
increased neutrophils production by the bone marrow. 
There was no significant difference in mean total 
WBCC between steady state and VOC (P>0.05). The 
neutrophil count was however significantly higher in 
VOC than in the steady state (P<0.01). This is in 
agreement with other studies, which show an increase 
in polymorphonuclear neutrophils in VOC over steady 
state values. This may also be due to increased 
demargination of intravascular neutrophils.15 The 
resulting raised total WBCC in steady state and during 
VOC when compared with controls was statistically 
significant (P<0.01). This has continued to affect the 
ability of clinicians to predict the presence of bacteria 
infections from leucocyte counts in sickle cell 
anaemia patients.16, 18
The mean platelet count for steady state value is 
similar to the 320-327x109/l reported in other 
studies.13, 18 There was no significant difference 
between values in steady state and VOC. However, 
the steady state platelet count was significantly higher 
than control (P<0.01). The platelet count in VOC was 
also significantly higher than control (P<0.05). This 
result is in agreement with previous studies, which 
show that platelet count is higher in SCA than in 
healthy control.13, 18 This may be due to loss of splenic 
platelet pool function in adult sickle cell patients 
consequent upon autosplectomy.19  
The mean cell volume (MCV) and the mean cell 
haemoglobin concentration (MCHC) were 
significantly higher in VOC than in steady state 
(P<0.01 and P<0.05 respectively) while the red cell 
distribution width (RDW) was significantly higher in 
the steady state than in VOC (P<0.05). This may be 
because SCA being a chronic haemolytic state 
stimulates haemopoiesis and haemopoietic activity is 
much higher during VOC than in the steady state. The 
cohort of fresh red blood cells being produced will 
have higher haematological indices .A higher MCHC 
may result from release of endogenous iron from 
broken down red cell haemoglobin synthesis. Also a 
higher MCHC may predispose to polymerization and 
hence VOC. The RDW, which is a measure of 
erythrocyte anisocytosis, was significantly higher in 
steady state and VOC than in control (P<0.01). This is 
in agreement with previous studies20 that show that 
SCA is associated with marked anisocytosis. This 
may be because with more rapid erythropoiesis, cells 
at different stages of maturation with different sizes 
are present at the same time. 
The mean HbF level found in this study in steady 
state, VOC and control are 2.17%±1.81, 2.05%± 1.19 
and 1.28%± 1.04 respectively.  Although the HbF 
level in   
 steady state is higher than during VOC, the result 
is not statistically significant. This is in agreement 
with an earlier study which reported no significant 
change in the HbF level during VOC and steady state 
period.21 A similar low mean HbF value of 
3.60%±1.96 in SCA patients was reported by Olatunji 
et al22 and also by Falusi et al.23 In contrast to these, 
other authors have reported much higher mean HbF 
value of 6.7-9.5%.21,24  This may be because many of 
these studies have a higher proportion of paediatric 
population than in this study, a coinheritance trait 
with thalassaemia  gene or a strong genetic 
component controlling the number of HbF containing 
cells (F cells) and the clinical status of the patient. 
Morrison et al25 has suggested that HbF level may fall 
following painful crisis. The HbF level has been 
shown to decline with age from about 80.4% at birth 
to 9.2% at 24 months.26 HbF values in steady state 
and VOC were significantly higher than in control 
(P<0.01), which is in agreement with other studies.21
Recent therapeutic approaches to SCD focus on 
attempt to reduce intracellular HbS polymerization by 
altering the haemoglobin specie.27 Pharmacological 
elevation of HbF has become the central focus of 
much laboratory and clinical research in recent years. 
Agents such as hydroxyurea (with or without 
recombinant human erythropoietin and butyrate 
compounds) elevate HbF and reduce HbS in a 
majority of sickle erythrocytes thus decreasing 
intracellular polymerization.27
The mean haemoglobin A2 (HbA2) level in this 
study for steady state, VOC and control were 
4.52%±1.61, 3.82%±1.27 and 2.13%±0.98 
respectively. The mean HbA2 for steady state is in 
agreement with the study by Hall et al28 who reported 
a mean HbA2 level of 5% with a range of 3.6-7.0% It 
also agrees with the 3.48%±0.50 for males and 
3.38%±0.62 for females reported by Serjeant et al.29 
The mean HbA2 level in steady state and in VOC was 
significantly higher than in control (P<0.01). This is 
also in agreement with previous studies.30 HbA2 value 
in steady state was significantly higher than in VOC, 
t-cal=3.43; P<0.01.It is taught that HbA2 may have a 
protective effect against complications of SCA by 
reducing minimum gelling concentration of 
haemoglobin S but only at considerably greater 
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